Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

Dennis Falzon, Holger J. Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer
European Respiratory Journal 2017 49: 1602308; DOI: 10.1183/13993003.02308-2016
Dennis Falzon
1Global TB Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: falzond@who.int
Holger J. Schünemann
2McMaster University Health Sciences Centre, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Harausz
3US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Licé González-Angulo
1Global TB Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Lienhardt
1Global TB Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernesto Jaramillo
1Global TB Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Weyer
1Global TB Programme, World Health Organization, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Choosing the treatment regimen in patients with confirmed multidrug- and rifampicin-resistant TB (MDR/RR-TB).

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Certainty of the evidence and definitions

    Certainty of the evidenceDefinition
    High (⊕⊕⊕⊕)Further research is very unlikely to change our confidence in the estimate of effect
    Moderate (⊕⊕⊕○)Further research is likely to have an important impact on our confidence in the effect and may change the estimate
    Low (⊕⊕○○)Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
    Very low (⊕○○○)Any estimate of effect is very uncertain
  • TABLE 2

    What are the most important outcomes to consider when making decisions on the treatment of drug-resistant tuberculosis (TB)?

    OutcomesMean score
    Adherence to TB treatment (treatment interruption due to nonadherence)6.8
    Avoiding adverse reactions from TB drugs7.0
    Avoiding the acquisition or amplification of drug resistance7.9
    Cure or successful completion by end of treatment9.0
    Culture conversion by month 67.4
    Death (survival) by the end of projected treatment8.1
    Treatment failure8.7
    Relapse7.7
    • Members of the Guideline Development Group scored TB outcomes according to their relative priority when making decisions on drug-resistant TB treatment. They were asked to take a societal perspective in rating the outcomes. 1–3 points: not important for making recommendations on drug-resistant TB treatment; 4–6 points: important but not critical for making recommendations on drug-resistant TB treatment; 7–9 points: critical for making recommendations on drug-resistant TB treatment.

  • TABLE 3

    General steps in designing the composition of a longer multidrug-resistant tuberculosis (MDR-TB) regimen#

    StepMedicines
    GroupingOptions
    1. Add one later-generation fluoroquinoloneA¶Levofloxacin (Lfx)
    Moxifloxacin (Mfx)
    Gatifloxacin (Gfx)
    2. Add one second-line injectable agentBAmikacin (Am)
    Capreomycin (Cm)
    Kanamycin (Km)
    (Streptomycin) (S)+
    3. Add two or more second-line agentsC¶Ethionamide/prothionamide (Eto/Pto)
    Cycloserine/terizidone (Cs/Trd)
    Linezolid (Lzd)
    Clofazimine (Cfz)
    4. Add pyrazinamide and any other first-line agent (if they can help strengthen the regimen)D1Pyrazinamide (Z)
    Ethambutol (E)
    High-dose isoniazid (Hh)
    5. Add bedaquiline or delamanidD2Bedaquiline (Bdq)§
    Delamanid (Dlm)§
    6. Add any of these agents (if the regimen cannot be composed otherwise)D3p-aminosalicylic acid (PAS)
    Imipenem–cilastatin (Ipm-Cln)ƒ
    Meropenem (Mpm)ƒ
    Amoxicillin–clavulanate (Amx-Clv)ƒ
    (Thioacetazone) (T)##
    • #: this stepwise approach guides the design of longer individualised regimens for patients who are not eligible for the World Health Organization-recommended shorter regimen (the composition of the shorter MDR-TB regimen is standardised) (see main text). The aim is to combine at least five effective agents in the intensive phase; more medicines may be included if they can safely increase the chances of cure. The choice of a medicine is based on the likelihood of its effectiveness, on reliable information on drug resistance and on the balance of expected benefits to risk. For instance, in case of nephrotoxicity or hearing loss, an injectable agent may be omitted and additional agents from Group C or D2 included. ¶: medicines in Groups A and C are shown in decreasing order of preference for use (subject to other considerations). +: streptomycin may substitute other injectable agents when the other three cannot be used; resistance to streptomycin alone does not qualify for the definition of extensively drug-resistant TB [50]. §: bedaquiline or delamanid may be added to the longer regimen to replace another second-line agent or to strengthen it in accordance with the interim policies [20, 21, 27]. ƒ: carbapenems and clavulanate are used together; clavulanate is only available in formulations combined with amoxicillin. ##: HIV status must be tested and confirmed to be negative before thioacetazone is started.

  • TABLE 4

    Summary of changes made by the 2016 updates to previous World Health Organization (WHO) policy on the treatment of drug-resistant tuberculosis (TB)

    The priority questions which were covered by the May 2016 update of the WHO treatment guidelines for drug-resistant TB related to the composition of treatment regimens for multidrug- and rifampicin-resistant TB (MDR/RR-TB); the effectiveness and safety of shorter MDR-TB regimens; the role of elective surgery in MDR-TB management; the treatment of isoniazid-resistant and Mycobacterium bovis tuberculosis; and the impact of delays in starting treatment. From June 2016, the WHO also reviewed additional data on bedaquiline and delamanid.
    The main changes in the 2016 recommendations are:
    • A second-line treatment is recommended for all patients with rifampicin-resistant tuberculosis, regardless of whether isoniazid resistance is confirmed or not.
    • A shorter MDR-TB treatment regimen is conditionally recommended for MDR/RR-TB patients under specific eligibility criteria.
    • Recommendations for the treatment of children with MDR/RR-TB are based on a first-ever meta-analysis of individual-level paediatric patient data for treatment outcomes.
    • Medicines used in the design of longer MDR-TB treatment regimens are now grouped differently, based upon current evidence on their effectiveness and safety. Clofazimine and linezolid are now considered more important MDR-TB regimen components, while p-aminosalicylic acid has been reclassified with agents used only as a last option. Clarithromycin and other macrolides are no longer included as medicines for the treatment of MDR/RR-TB. Delamanid may also be used in patients aged 6–17 years old.
    • An evidence-informed recommendation on partial resection lung surgery is now included.
    The evidence available on the treatment of isoniazid-resistant TB and on the delay to starting MDR-TB treatment could not address the guideline questions. There were very few published studies on the treatment of M. bovis and the regimens differed, precluding any attempt at formulating recommendations of clinical use.
    The scope of the 2016 update of MDR-TB treatment policy did not include other aspects of the programmatic management of drug-resistant TB for which no substantive new evidence had emerged since the previous revision. The 2011 recommendations regarding the testing of TB patients for rifampicin resistance, the monitoring of treatment response, the duration of longer regimens, the delay in starting antiretroviral therapy in MDR-TB patients with HIV infection and models of care thus continue to apply until future evidence reviews show a need for revision. No change is made to the recommended use of bedaquiline from those of 2013 [20, 33].

Supplementary Materials

  • Figures
  • Tables
  • Supplementary Material

    Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

    Supplementary material ERJ-02308-2016_Supplementary_material

  • Supplementary Material

    D. Falzon ERJ-02308-2016_Falzon

    L. Gonzalez-Angulo ERJ-02308-2016_Gonzalez-Angulo

    E. Harausz ERJ-02308-2016_Harausz

    E. Jaramillo ERJ-02308-2016_Jaramillo

    C. Lienhardt ERJ-02308-2016_Lienhardt

    H.J. Schuenemann ERJ-02308-2016_Schuenemann

    K. Weyer ERJ-02308-2016_Weyer

PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 3 Table of Contents
European Respiratory Journal: 49 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Dennis Falzon, Holger J. Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer
European Respiratory Journal Mar 2017, 49 (3) 1602308; DOI: 10.1183/13993003.02308-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Dennis Falzon, Holger J. Schünemann, Elizabeth Harausz, Licé González-Angulo, Christian Lienhardt, Ernesto Jaramillo, Karin Weyer
European Respiratory Journal Mar 2017, 49 (3) 1602308; DOI: 10.1183/13993003.02308-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Material and methods
    • Results
    • Discussion
    • Supplementary material
    • Disclosures
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • ERS technical standards: GLI reference values for TLCO
  • ERS/ESICM/ESCMID/ALAT guidelines for management of HAP/VAP
  • ERS guidelines for the management of adult bronchiectasis
Show more Task Force Reports

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society